Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amphastar Has First US Glucagon Rival

FDA Approves First Generic Version Of Eli Lilly’s Glucagon Emergency Kit

Executive Summary

Amphastar has secured the first US approval for a generic version of Eli Lilly’s glucagon emergency kit.

You may also be interested in...

Amphastar Eyes Sun Pharma Showdown With US Ganirelix Approval

Amphastar is celebrating what it says is its fourth injectable peptide product approval from the USFDA with its generic version of Organon’s ganirelix acetate, in the process setting up a rivalry with Sun Pharma and commercial partner Ferring Pharmaceuticals.

Amphastar Grows With Primatene Mist, Epinephrine And Glucagon

Amphastar has reported double-digit growth in the fourth quarter of 2021, as the company sees sales growth from Primatene Mist, epinephrine products and glucagon. The company also revealed that it is anticipating a Q3 FY22 launch of vasopressin.

Growing Complex Generic Application Load May Force US FDA Staffing Changes

Complex products are slowly gaining a larger share of ANDA submission and approval totals, which could mean the FDA has to adapt its in-house expertise to compensate.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts